Skip to main content

Table 1 Summary of real world drug doses and costs by line of treatment

From: Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data

  Mean price (€/mg) N   Treatment duration (days) Dose mg/daya Treatment cost (€/dayb)
First line
 Sunitinib 3.52 766 Mean (SD) 71(99) 48(7) 168(27)
Median [Range] 28[0.23–1043] 50[13–100] 176[6–352]
 Sorafenib 0.14 48 Mean (SD) 43(42) 388(151) 54(21)
Median [Range] 31[1–182] 400[200–800] 56[28–112]
 Pazopanib 0.12 19 Mean (SD) 88(87) 716(167) 86(20)
Median [Range] 49[7–308] 800[400–800] 96[48–96]
 Bevacizumab 2.43 52 Mean (SD) 6(10) 706(224) 1684(578)
Median [Range] 3[1–52] 720[10–1245] 1725[24–3025]
 Everolimus 16.19 10 Mean (SD) 86(143) 11(3) 178(51)
Median [Range] 28[7–455] 10[10–20] 162[162–324]
 Temsirolimus 24.26 156 Mean (SD) 9(12) 26(5) 562(192)
Median [Range] 6[1–77] 25[15–57] 607[87–1379]
Second line
 Sunitinib 3.52 23 Mean (SD) 61(41) 51(23) 180(80)
Median [Range] 28[28–140] 50[25–150] 176[88–528]
 Sorafenib 0.14 61 Mean (SD) 73(86) 626(310) 88(43)
Median [Range] 56[7–623] 400[200–1600] 56[28–224]
 Axitinib 13.51 18 Mean (SD) 58(53) 11(3) 149(47)
Median [Range] 49[7–238] 10[5–20] 135[68–270]
 Bevacizumab 2.43 4 Mean (SD) 7(7) 745(209) 1810(508)
Median [Range] 4[2–17] 745[490–1000] 1810 [1191–2430]
 Everolimus 16.19 72 Mean (SD) 118(142) 10(1) 158(19)
Median [Range] 66[14–784] 10[5–10] 162[81–162]
 Temsirolimus 24.26 16 Mean (SD) 9(8) 25(0) 607(0)
Median [Range] 7[1–29] 25[25–25] 607[607–607]
Third line
 Sunitinib 3.52 2 Mean (SD) 70(59) 50(0) 176(0)
Median [Range] 70[28–112] 50[50–50] 176[176–176]
 Sorafenib 0.14 14 Mean (SD) 87(109) 671(347) 94(49)
Median [Range] 56[14–441] 800[200–1600] 112[28–224]
 Axitinib 13.51 3 Mean (SD) 93(89) 12(8) 158(103)
Median [Range] 49[35–196] 10[5–20] 135[68–270]
 Bevacizumab 2.43 3 Mean (SD) 9(7) 850(140) 2066(340)
Median [Range] 6[4–17] 850[710–990] 2066 [1725–2405]
 Everolimus 16.19 13 Mean (SD) 74(115) 10(0) 162(0)
Median [Range] 28[6–427] 10[10–10] 162[162–162]
 Temsirolimus 24.26 12 Mean (SD) 11(10) 27(7) 613(240)
Median [Range] 8[2–31] 25(25–50] 606[87–1213]
  1. aDuration does not include off treatment periods
  2. bDose per day during which treatment is administered